AbbVie | ABBV - PE Price to Earnings


AbbVie reported 23.96 in PE Price to Earnings for its fiscal quarter ending in June of 2026.





Pe Change Date
AbbVie 23.96 0.93 Jun/2026
Abbott 23.85 1.08 Jun/2026
ALKERMES 135.81 96.48 Jun/2026
Amgen 18.07 1.77 Jun/2026
AstraZeneca 25.34 4.25 Jun/2026
Biogen 23.23 9.53 Jun/2026
BioMarin Pharmaceutical 15.28 3.96 Mar/2026
Bristol-Myers Squibb 16.14 7.06 Jun/2026
Eisai 26.55 9.06 Jun/2026
Eli Lilly 32.9 7.37 Jun/2026
Gilead Sciences 13.51 4.2 Jun/2026
GlaxoSmithKline 10.63 4.24 Jun/2026
J&J 29.43 4.9 Jun/2026
Medtronic 19.66 3.1 Mar/2026
Merck 32.26 15.74 Jun/2026
Neurocrine Biosciences 22.1 5.99 Jun/2026
Novartis 22.41 2.24 Jun/2026
Pacira 35.68 2.9 Jun/2026
Perrigo 27.45 31.51 Mar/2026
Pfizer 11.48 2.16 Jun/2026
Regeneron Pharmaceuticals 15.46 9.68 Jun/2026
Roche Holding 16.48 0.39 Jun/2026
Sanofi 18.96 7.12 Jun/2026
UCB 29.7 5.52 Dec/2025
United Therapeutics 20.42 3.1 Mar/2026
Vertex Pharmaceuticals 28.05 2.22 Jun/2026
Zoetis 18.8 1.62 Mar/2026